Trillium Therapeutics (NASDAQ: TRIL) is one of 95 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Trillium Therapeutics to similar businesses based on the strength of its analyst recommendations, risk, dividends, institutional ownership, profitability, valuation and earnings.
This table compares Trillium Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Trillium Therapeutics Competitors||-912.91%||-186.15%||-28.31%|
Volatility and Risk
Trillium Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Trillium Therapeutics’ rivals have a beta of 1.13, indicating that their average share price is 13% more volatile than the S&P 500.
Institutional & Insider Ownership
48.0% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 18.5% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for Trillium Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Trillium Therapeutics Competitors||122||463||1154||11||2.60|
Trillium Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 177.78%. As a group, “Biotechnology” companies have a potential upside of 52.77%. Given Trillium Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Trillium Therapeutics is more favorable than its rivals.
Valuation and Earnings
This table compares Trillium Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Trillium Therapeutics||N/A||-$28.62 million||-1.45|
|Trillium Therapeutics Competitors||$224.52 million||$58.08 million||-1.09|
Trillium Therapeutics’ rivals have higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Trillium Therapeutics beats its rivals on 7 of the 12 factors compared.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.